$166 billion in discounts intended for patients goes to middlemen New Brunswick, Jan. 29, 2020 ― An important new study sheds light on the dynamics
Although New Jersey’s biopharmaceutical sector opposed H.R. 3, we share its overriding goal – to ensure that patients can access the treatments and cures that
From NJBIZ: The history of manufacturing in New Jersey is the history of manufacturing in America. Historians can trace the birth of the country’s political
HINJ President and Chief Executive Officer Dean J. Paranicas has issued the following statement about the full repeal of the medical device excise tax: “Patients,
HINJ honored Prof. Jay A. Tischfield of Rutgers University–New Brunswick today (Dec. 9, 2019) “in recognition of innovative and creative leadership in genetics research, scholarship
For the first time in human history, we have cured hepatitis C – the days of liver transplants and life-long treatments are fast disappearing. We
Steve Issenman
Senior V.P.
732-729-9621
issenman@hinj.org
